■ KEY POINTS
This year, the CDC is recommending vaccinating people 65 years and older (rather than age 50 and older) and is advising healthy people between the ages of 2 years and 64 years to forgo immunization. The live-attenuated, intranasal influenza vaccine is another option.
Four antiviral agents are available for treating influenza. Three of these agents are also approved for preventing influenza, but they should be used mainly in the setting of an outbreak or in those who cannot be immunized but are at high risk of complications from influenza.
General measures to avoid transmission of respiratory viruses, particularly hand-washing and covering coughs and sneezes, are very effective and should be emphasized this flu season.
Giving smaller doses of the inactivated vaccine either intramuscularly or intradermally appears promising but is not currently recommended N OCTOBER 2004, the nation was informed that almost half its supply of influenza vaccine will not be released, owing to contamination problems affecting one of its two suppliers. The sudden shortage has resulted in panic among patients and health care providers alike.
A bit of good news is that the flu season that ended in September in the Southern Hemisphere was associated with mild-to-moderate disease activity. 1 The A (H3N2)/ Fujian/411/02-like strain predominated, a strain similar to the A (H3N2) component of the 2004-2005 influenza vaccine. During October [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] 2004 , only sporadic influenza activity was reported in the United States. 1 The bad news is that we will have to ration supplies, reserving what we have for people at highest risk. Measures to this end are in place. Cooperation from the public and health care providers will be imperative to implement these measures.
■ HOW AND WHY THE SHORTAGE OCCURRED
In 1994, there were five manufacturers of influenza vaccine in the United States. Since then, several companies decided to stop making it, owing to difficult production procedures, strict government regulations, unpredictable consumer demand, a relatively low profit margin compared with other pharmaceutical products, and lack of liability protection from expensive lawsuits.
At the same time, since Medicare began reimbursing for influenza vaccination in 1991, demand for vaccine has been rising, reaching 83 million doses in the 2003-2004 season. However, since the severity of any particular I influenza season is difficult to predict, vaccine manufacturers expect to discard about 10% of their product each year.
Influenza vaccine differs from other vaccines in that it has to be manufactured anew every year to match the expected circulating influenza strains. The current production process, which relies on growing the virus in eggs, starts in late February of each year when the World Health Organization decides on the three vaccine components (two type A viruses and one type B). This process must follow a tight schedule, since starting early may omit important emerging strains, and delaying too long would not give enough time for the tedious procedures to be completed in time before the flu season.
Even though there has been an increase in investment in influenza-related activities under President Bush from $39 million to $283 million, much more is needed to shift vaccine development from the cumbersome egg-based production process to new cell culture technologies.
The only two companies that currently make the flu shot for the United States, Aventis and Chiron, were poised to supply • Adults and children with chronic medical conditions, including heart disease, lung disease, kidney disease, metabolic disease, hemoglobinopathies, or immunosuppression caused by diseases such as human immunodeficiency virus infection or by medications, such as in bone marrow and organ transplant recipients. • All women who will be pregnant this flu season, regardless of which trimester of pregnancy they will be in. If someone belonging to one of the above groups attempts to get vaccinated and his or her health care provider cannot provide the vaccine, he or she should be advised to contact the local health department, or to search for public clinics that may have the flu shot by accessing www.findaflushot.com/lungusa. [However, when CCJM staff checked this web site in mid-November, many zip codes did not show any flu shot clinics being conducted.]
Whom not to vaccinate
It is more important in the setting of shortage to remember whom not to give the flu shot to:
• Children younger than 6 months • Healthy people 2 to 64 years old • People with known anaphylactic hypersensitivity to eggs or to other components of the influenza vaccine. Mild upper respiratory tract infections, particularly in the absence of fever, should not preclude vaccination.
■ WHAT ELSE CAN BE DONE?
In addition to the above revised recommendations, the following measures should aid in resolving the shortage problem.
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Promoting good health habits
Good health habits that prevent the spread of influenza include hand-washing, covering coughs and sneezes, avoiding touching one's nose, eyes, or mouth, particularly during upper respiratory infections, staying away from people with upper respiratory infections, and staying home from work or school if one suspects he or she has influenza. General healthy habits, including getting adequate rest, drinking plenty of fluids, eating a healthy diet, and exercising regularly, should also aid in maintaining the immune system to fight off infection.
Looking for more vaccine
Aventis recently announced a plan to redistribute 22.4 million doses of its remaining supply and to manufacture 2.6 million additional doses by January 2005.
Officials from the US Food and Drug Administration (FDA) are looking to other countries to get additional doses of flu vaccine this season. There are approximately 18 influenza vaccine manufacturers worldwide.
The government is cracking down on fraudulent merchants and those profiteering from the vaccine shortage, and warns of vaccine scams on the Internet.
Giving nasal vaccine
Healthy people ages 5 to 49 years old can receive the intranasal, live-attenuated influenza vaccine, even if they care for babies under 6 months of age or if they are in close contact with immunosuppressed individuals who are not deemed to be severely immunosuppressed, such as hematopoietic stem cell transplant recipients. Similarly, health care providers can receive the live-attenuated vaccine if they are not in contact with severely immunosuppressed patients. 3 (Although the CDC does not specify what types of transplant recipients are severely immunosuppressed, I believe all bone marrow and solid organ transplant recipients should be considered so, at least for 6-12 months after transplantation.)
This year, only 1.1 million doses of this vaccine were made, but the manufacturer has recently announced that 2 million additional doses will be available by the end of December.
When to use antiviral medications
Influenza antiviral medications should be judiciously used for both prevention and treatment of influenza. 4 The CDC encourages the use of either amantadine or rimantadine for prophylaxis and use of oseltamivir or zanamivir for treatment (TABLE 1) .
People who are at high risk for serious complications of influenza benefit the most from antiviral medications. Patients should be treated if they present within 2 days of the onset of illness and either have life-threatening influenza or are at high risk for serious complications of influenza. Symptoms that should prompt the use of an antiviral agent are the sudden onset of fever, headache, and dry cough during the epidemic period.
In addition, antiviral prophylaxis should be given to residents of nursing homes and hospitals in which there is an institutional outbreak, regardless of their vaccination status. In this situation the health care providers 
